MX395015B - Composiciones microencapsuladas de cannabinoides - Google Patents

Composiciones microencapsuladas de cannabinoides

Info

Publication number
MX395015B
MX395015B MX2021010033A MX2021010033A MX395015B MX 395015 B MX395015 B MX 395015B MX 2021010033 A MX2021010033 A MX 2021010033A MX 2021010033 A MX2021010033 A MX 2021010033A MX 395015 B MX395015 B MX 395015B
Authority
MX
Mexico
Prior art keywords
cannabinoids
compositions
microencapsulated compositions
microencapsulated
encapsulated
Prior art date
Application number
MX2021010033A
Other languages
English (en)
Other versions
MX2021010033A (es
Inventor
Justin Kirkland
William Kleidon
Original Assignee
Ojai Energetics Pbc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ojai Energetics Pbc filed Critical Ojai Energetics Pbc
Publication of MX2021010033A publication Critical patent/MX2021010033A/es
Publication of MX395015B publication Critical patent/MX395015B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/001—Spread compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/52—Liquid products; Solid products in the form of powders, flakes or granules for making liquid products ; Finished or semi-finished solid products, frozen granules
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/733—Alginic acid; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)

Abstract

La presente invención se refiere a composiciones de cannabinoides. Estas composiciones se pueden encapsular (por ejemplo, microencapsular). En particular, estas composiciones se pueden administrar a un sujeto, tal como a través de consumo oral o tratamiento tópico.
MX2021010033A 2014-12-12 2015-12-11 Composiciones microencapsuladas de cannabinoides MX395015B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462091445P 2014-12-12 2014-12-12
US201562128761P 2015-03-05 2015-03-05
PCT/US2015/065268 WO2016094810A2 (en) 2014-12-12 2015-12-11 Microencapsulated cannabinoid compositions

Publications (2)

Publication Number Publication Date
MX2021010033A MX2021010033A (es) 2022-08-25
MX395015B true MX395015B (es) 2025-03-24

Family

ID=56108379

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017007550A MX385464B (es) 2014-12-12 2015-12-11 Composiciones microencapsuladas de cannabinoides
MX2021010033A MX395015B (es) 2014-12-12 2015-12-11 Composiciones microencapsuladas de cannabinoides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017007550A MX385464B (es) 2014-12-12 2015-12-11 Composiciones microencapsuladas de cannabinoides

Country Status (12)

Country Link
US (2) US10080736B2 (es)
EP (1) EP3229789A4 (es)
JP (3) JP2018505912A (es)
CN (2) CN107205981A (es)
AU (2) AU2015360349B2 (es)
BR (1) BR112017012434A2 (es)
CA (1) CA2970651C (es)
EA (1) EA201791299A1 (es)
HK (1) HK1244710A1 (es)
IL (2) IL252881B (es)
MX (2) MX385464B (es)
WO (1) WO2016094810A2 (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
CA2985332C (en) 2015-05-18 2023-01-03 5071, Inc. Homogenous cannabis compositions and methods of making the same
US10369178B2 (en) * 2016-03-06 2019-08-06 Resurgent Pharmaceuticals, Inc. Tobacco products with cannabinoid additives and methods for reducing the harm associated with tobacco use
EP3442521A4 (en) 2016-04-15 2020-01-01 SRE Wellness, Inc. SWEETENERS AND ELIXIRS INFused WITH CANNABIS
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
WO2017180954A1 (en) 2016-04-15 2017-10-19 Ronald Silver Method of making cannabis oil hydrophiilic using emulsifiers and related cannabinoid compositions
JP7454332B2 (ja) 2016-06-15 2024-03-22 オーハイ エナジェティクス ピービーシー 酸化ストレスを低減するための方法および組成物
AU2017286656A1 (en) * 2016-06-15 2019-01-17 Ojai Energetics Pbc Methods and compositions for potentiating stem cell therapies
BR112019001852A2 (pt) 2016-08-03 2019-05-07 Zelda Therapeutics Operations Pty Ltd composição de cannabis
KR20190034576A (ko) 2016-08-03 2019-04-02 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
AU2017357164A1 (en) * 2016-11-14 2019-05-30 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018112138A1 (en) * 2016-12-15 2018-06-21 Anavi Goffer Sharon Treatment of mental, movement and behavioral disorders
MX2019007496A (es) * 2016-12-20 2019-10-30 Tilray Inc Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil.
AU2018239222A1 (en) * 2017-03-18 2019-09-26 Thomas A. Asquith Pet food including cannabidiolic acid
EP3600285A4 (en) * 2017-03-27 2021-01-13 Patagonia Pharmaceuticals, LLC TOPICAL COMPOSITIONS AND METHODS OF TREATMENT
US11096349B2 (en) * 2017-08-02 2021-08-24 Insectergy, Llc Cannabis farming systems and methods
WO2018217803A2 (en) * 2017-05-22 2018-11-29 Growblox Life Sciences L.L.C. Myrcene-containing complex mixtures targeting trpv1
CN111093633A (zh) * 2017-05-26 2020-05-01 奥特姆医药公司 双相大麻素递送
WO2018228616A1 (en) * 2017-06-16 2018-12-20 Bednarik Frantisek A composite mixture comprising cannabis sativa
KR20200104278A (ko) 2017-06-19 2020-09-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 수면 장애 조성물 및 그의 치료
EP3645119A1 (en) * 2017-06-30 2020-05-06 Creso Pharma Switzerland GmbH Veterinary granules composition containing hemp extract
CA3069694A1 (en) * 2017-07-14 2019-01-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
CO2017007962A1 (es) * 2017-08-04 2018-04-19 Alsec Alimentos Secos S A S Nanoparticulas oleosas de cannabis microencapsuladas en polvo
CN111212638A (zh) * 2017-09-08 2020-05-29 西卡恩治疗公司 包括大麻素和千日菊素的组合物
CN107903655A (zh) * 2017-10-18 2018-04-13 湖北科技学院 一种从桂花果皮中提取黑色素的方法及其应用
US11857530B2 (en) 2017-10-30 2024-01-02 Endocanna Health, Inc. Cannabinoid formulations
WO2019135224A1 (en) * 2018-01-03 2019-07-11 Icdpharma Ltd. Taste-enhanced cannabinoid submicron emulsion syrup compositions
WO2019136351A1 (en) * 2018-01-05 2019-07-11 Altus Labs, Llc Personal care compositions
US12035732B1 (en) * 2018-01-29 2024-07-16 Nouv Eau Inc. Composition of matter and method of use for wine health mixtures
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
ES2977485T3 (es) * 2018-03-14 2024-08-26 Poviva Corp Administración transdérmica y/o dérmica de agentes activos lipofílicos
MX2020010603A (es) * 2018-04-09 2021-02-02 Ellevet Sciences Extracto de cáñamo para tratamiento de dolor en animales.
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
BR112020025628A2 (pt) * 2018-06-15 2021-03-23 CannPal Animal Therapeutics Limited composição de canabinóide e métodos de tratamento usando o mesmo
GB2600893B (en) * 2018-08-06 2022-12-21 Ubeauty Global A tanning composition
CN109045045B (zh) * 2018-08-14 2020-10-09 淮南师范学院 一种治疗心脑血管疾病的中药活性成分组合物
US11690963B2 (en) 2018-08-22 2023-07-04 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
US11517685B2 (en) 2019-01-18 2022-12-06 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
TWI888357B (zh) 2018-08-22 2025-07-01 美商奎諾維亞公司 用於產生供人體吸入的氣霧的電子裝置
US20210186870A1 (en) * 2018-08-27 2021-06-24 Emerald Health Therapeutics Canada Inc. Improved cannabinoid bioavailability
US11147775B2 (en) 2018-09-04 2021-10-19 Babak Ghalili Cannabinoid and menthol gel compositions, patches and methods
US10966924B2 (en) 2018-09-04 2021-04-06 Babak Ghalili Veterinary cannabinoid, menthol and anesthetic compositions and methods
US11185526B2 (en) 2018-09-04 2021-11-30 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US10751299B2 (en) 2018-09-04 2020-08-25 Babak Ghalili Cannabinoid and menthol compositions and methods
IL261774B (en) * 2018-09-13 2020-04-30 Unv Medicine Ltd Preparations for the treatment of skin problems
MX2021003832A (es) * 2018-10-04 2021-09-08 India Globalization Capital Inc Metodo y composicion para aliviar la fatiga y restaurar la energia.
CA3116862A1 (en) * 2018-10-18 2020-04-23 Respira Technologies, Inc. Electronic device for producing an aerosol for inhalation by a person
CN111183989A (zh) * 2018-11-14 2020-05-22 北京中以新农高科商务咨询有限公司 包含胶囊化挥发性精油和溶解在其中的聚合物的农用制剂
GB2579179A (en) * 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
US11458092B2 (en) 2018-12-14 2022-10-04 NuVessl, Inc. Composition with enhanced passenger molecule loading
GB2598458A (en) * 2018-12-18 2022-03-02 Ojai Energetics Pbc Cannabinoid compositions for virtual and augmented reality experiences
US20220054380A1 (en) * 2018-12-25 2022-02-24 Epm (Ip), Inc. Cannabidioloic acid esters for cosmetic or edible compositions
AU2019412825A1 (en) * 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
EP3902538A4 (en) * 2018-12-29 2023-01-18 Buzzelet Development And Technologies Ltd ISOLATED OR SYNTHETIC CANNABINOID COMPOSITIONS WITH SELECTED TERPEN BLEND AND METHODS OF USE THEREOF
EP3911148A4 (en) * 2019-01-17 2022-10-12 Synthonics, Inc. SOLID MICELLAR COMPOSITIONS OF CANNABINOID ACIDS
WO2020157639A1 (en) * 2019-01-29 2020-08-06 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid composition and method of treatment for treating conditions and/or symptoms associated with autism spectrum disorder
CA3130763A1 (en) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthesis of cannabinoids and cannabinoid precursors
CA3134241C (en) * 2019-03-21 2022-10-25 Alvit Lcs Pharma Ltd. Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases
KR102862524B1 (ko) * 2019-05-06 2025-09-22 트랜스포트 오쏘리티, 인크. 대마 식용품 제조 시스템 및 방법, 및 결과적인 식용 제품
US20220233463A1 (en) * 2019-05-16 2022-07-28 Buzzelet Development And Technologies Ltd. Local anesthetic comprising a trp channel modulator
CN110025595A (zh) * 2019-05-27 2019-07-19 西宝生物科技（上海）股份有限公司 一种高稳定可水溶性工业大麻cbd微囊的制备方法
WO2020264052A1 (en) * 2019-06-24 2020-12-30 Hempvana, Llc Compositions comprising cannabis sativa oil and uses thereof
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
WO2020263285A1 (en) * 2019-06-28 2020-12-30 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
MX2022000027A (es) * 2019-07-02 2022-04-11 Ellevet Sciences Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
US20210023023A1 (en) * 2019-07-25 2021-01-28 Vasayo, Llc Liposomal nutraceutical compositions and methods of making the same
US20210023005A1 (en) 2019-07-26 2021-01-28 Landsteiner Scientific S.A. De C.V. Cannabinoid-containing compositions in the form of spheres or sphere-like particles, methods for their preparation, and therapeutic applications
CA3149915A1 (en) * 2019-08-06 2021-02-11 Nuka Enterprises Consumable compositions and methods of producing the same
CA3148970A1 (en) * 2019-08-26 2021-03-04 Gianna Marie FILIPETTO Method and apparatus for the infusion of cannabinoids into a shelf-stable food composition
US20210169820A1 (en) * 2019-09-12 2021-06-10 Nulixir Inc. Controlled release concentrate and suspensions including the same
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
US20210113783A1 (en) 2019-10-20 2021-04-22 Respira Technologies, Inc. Electronic devices and liquids for aerosolizing and inhaling therewith
WO2021092428A1 (en) * 2019-11-08 2021-05-14 Ellevet Sciences Hemp extract and methods of use thereof
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
WO2021130728A1 (en) * 2019-12-28 2021-07-01 Buzzelet Development And Technologies Ltd. Liquid compositions comprising terpenes and cannabinoids
EP3861996A1 (en) * 2020-02-04 2021-08-11 I+Med S. Coop. Controlled release system of phytocannabinoids formulations soluble in aqueous media, methods and uses thereof
WO2021163802A1 (en) * 2020-02-20 2021-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Use of castalagin or analogs thereof for anti-cancer efficacy and to increase the response to immune checkpoint inhibitors
WO2021178465A1 (en) * 2020-03-02 2021-09-10 Clear Lake Research, Llc Buccal and enteric delivery of fatty acids with oral hygiene practices
WO2021178579A1 (en) * 2020-03-03 2021-09-10 Alte Verde Llc Cannabis treatment of insomnia, pain, and skin conditions
EP4125834A4 (en) * 2020-03-30 2024-05-08 Ojai Energetics PBC SYSTEMS, METHODS AND COMPOSITIONS FOR INFECTIONS
US12491199B2 (en) 2020-04-17 2025-12-09 University Of Connecticut Polycannabinoids, compounds, compositions and methods of use
WO2021216640A1 (en) * 2020-04-21 2021-10-28 Coolhouse Sourcing Llc Composition, article and method for affecting a mammal
US12471625B2 (en) 2020-11-01 2025-11-18 Qnovia, Inc. Electronic devices and liquids for aerosolizing and inhaling therewith
CA3204196A1 (en) * 2020-11-06 2022-05-12 Zelira Therapeutics Operations Pty Ltd Cannabinoid encapsulation technology
WO2022122471A1 (en) * 2020-12-09 2022-06-16 I+Med S. Coop. Composition comprising sea water and cannabinoid loaded submicroparticles for pharmaceutical, nutraceutical and cosmetic applications
CN112472661A (zh) * 2020-12-11 2021-03-12 云南苏旺润生物医药有限公司 一种大麻二酚按摩油组合物及其制备方法和应用
US20220218649A1 (en) * 2021-01-07 2022-07-14 Mai Nguyen Composition for treating opioid withdrawal and method of manufacture
KR102278512B1 (ko) 2021-01-19 2021-07-20 정진욱 광화학 반응시켜 카나비디올 및 풀빅산을 함유하며, 상기 카나비디올 및 풀빅산 성분이 식용 곤충, 파충류, 연체류, 및 가축류로의 천이 가능한 사료 조성물 및 이의 제조방법
US20220266206A1 (en) * 2021-02-19 2022-08-25 Gaia Botanicals Llc Dba Bluebird Botanicals Formulation and process for manufacturing a heat stable oil-in-water emulsion for cannabis beverages in plastic bottles
IT202100006893A1 (it) * 2021-03-22 2022-09-22 Kolinpharma S P A Una formulazione in forma di microgranuli comprendente un estratto o molecola di origine vegetale avente effetti gastrolesivi o instabilità a ph acido, e una matrice gastroresistente
US11844361B2 (en) 2021-04-08 2023-12-19 Wiparo Biomed Limited Stem cell boosting chocolate composition
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
CN113332278A (zh) * 2021-06-03 2021-09-03 威海华新药业集团有限公司 一种靛红和二氢大麻酚复合物及其医疗用途
US20240285723A1 (en) * 2021-06-24 2024-08-29 Ramot At Tel-Aviv University Ltd. Combination compositions for the treatment of pathogen infections and associated complications
WO2023278768A1 (en) * 2021-06-30 2023-01-05 Demetrix, Inc. Alleviation of itching sensations using cannabinoid compounds
EP4373507A4 (en) * 2021-07-23 2025-05-14 Ojai Energetics PBC METHODS AND COMPOSITIONS FOR MICROENCAPSULED COMPOUNDS
EP4134073A1 (en) 2021-08-11 2023-02-15 HM HerbaMedica GmbH Pharmaceutical compositions comprising dendritic nanocarriers and cannabis active agents
CA3130284A1 (en) * 2021-09-09 2023-03-09 Faezeh Dousty Cannabinoid-humic substances composition and method of making the same
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
EP4499109A1 (en) * 2022-03-25 2025-02-05 Ojai Energetics PBC Psychedelic compositions and methods for forming the same
TW202404490A (zh) 2022-04-22 2024-02-01 美商奎諾維亞公司 用於霧化和吸入液體的電子設備
WO2023245107A1 (en) * 2022-06-15 2023-12-21 Phyto Tech Corp. Microencapsulation of cannabidiol or its mixture with nicotine for oral and topical administration
CN115068441B (zh) * 2022-06-30 2023-04-14 东北农业大学 一种水溶性大麻二酚微胶囊及其制备方法
CN115364050B (zh) * 2022-08-02 2023-07-18 无锡诺平医药科技有限公司 H2cbd乳液、制备方法及其药物应用
EP4499286A1 (en) * 2022-11-14 2025-02-05 Medisca Pharmaceutique Inc. Methods and systems for making oil-loaded powders and use thereof
WO2024154119A1 (en) * 2023-01-19 2024-07-25 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Enriched pelargonium graveolens extracts for the treatment of traumatic brain injuries
US12480074B2 (en) 2023-08-04 2025-11-25 University Of Connecticut Natural and synthetic cannabinoids as fluorescent tags; compositions, methods, and applications
US20250099382A1 (en) * 2023-09-26 2025-03-27 Robert Austin Chittenden Colloidal suspension of nutraceutical ingredients to treat traumatic brain injury
WO2025116961A1 (en) * 2023-11-27 2025-06-05 J.D.I.P., Llc Cannabis compositions, oral products, and methods of making same

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3456049A (en) 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
JPS5948414A (ja) * 1982-09-10 1984-03-19 Asahi Denka Kogyo Kk ビタミンｅの水溶性製剤
JPS6051104A (ja) * 1983-08-30 1985-03-22 Ajinomoto Co Inc ビタミンｅ含有水性液剤
JPS6398369A (ja) * 1986-10-14 1988-04-28 Maruzen Kasei Kk 飲料用クラウデイ−
US4888194A (en) * 1986-12-10 1989-12-19 Borden, Inc. Shelf-stable aseptic dairy product
US5674522A (en) * 1993-10-07 1997-10-07 Mcneil-Ppc, Inc. Beverage concentrate for drug delivery
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
EP1409473A2 (en) 2001-03-07 2004-04-21 Websar Innovations Inc. CONVERSION OF CBD TO $g(D)?8 -THC AND $g(D)?9 -THC
DE10258867A1 (de) * 2002-12-17 2004-07-08 Bayer Cropscience Gmbh Mikroemulsionskonzentrate
ES2235642B2 (es) * 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
GB0409104D0 (en) * 2004-04-23 2004-05-26 Norgine Europe Bv Compressed pharmaceutical compositions
CN1968684A (zh) 2004-06-17 2007-05-23 森林实验室公司 美金刚的调释制剂
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
US8017152B2 (en) * 2005-05-27 2011-09-13 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
CA2607600A1 (en) 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
US20080242741A1 (en) * 2007-03-30 2008-10-02 Wayne Jeffrey Perry Intranasal drug delivery system
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
EA201200428A1 (ru) * 2009-10-09 2013-02-28 Атеронова Оперэйшионс, Инк. Композиция и способ для лечения ожирения
CA2792330C (en) * 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
US20120043242A1 (en) 2010-08-19 2012-02-23 Andrew David Hospodor Medicinal cannabis fatty foodstuff
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
EP2648552A1 (en) * 2010-12-10 2013-10-16 The Governors of the University of Alberta Barley protein microcapsules
WO2013009928A1 (en) 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
GB2514054A (en) * 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
ES2739194T3 (es) * 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
CA2895805A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
CA3012383C (en) 2013-02-28 2021-03-02 Teewinot Technologies Limited Biosynthesis of cannabinoids
AU2014347807A1 (en) * 2013-10-31 2016-05-26 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
SG11201702543YA (en) 2014-09-29 2017-04-27 Tan Barrie Non-synthetic emulsion-based lipid formulations and methods of use

Also Published As

Publication number Publication date
CA2970651A1 (en) 2016-06-16
AU2021200019A1 (en) 2021-03-18
MX2017007550A (es) 2018-05-04
AU2021200019B2 (en) 2022-06-02
CN107205981A (zh) 2017-09-26
JP2024015115A (ja) 2024-02-01
IL252881B (en) 2022-06-01
JP2022023230A (ja) 2022-02-07
MX2021010033A (es) 2022-08-25
WO2016094810A3 (en) 2016-10-13
AU2015360349B2 (en) 2020-10-08
EP3229789A4 (en) 2018-08-08
US20170172977A1 (en) 2017-06-22
MX385464B (es) 2025-03-18
IL292818A (en) 2022-07-01
AU2015360349A1 (en) 2017-07-06
EA201791299A1 (ru) 2017-12-29
US10080736B2 (en) 2018-09-25
US20180344686A1 (en) 2018-12-06
JP2018505912A (ja) 2018-03-01
NZ732700A (en) 2024-07-05
EP3229789A2 (en) 2017-10-18
HK1244710A1 (zh) 2018-08-17
CN118436616A (zh) 2024-08-06
WO2016094810A2 (en) 2016-06-16
CA2970651C (en) 2020-09-29
IL252881A0 (en) 2017-08-31
BR112017012434A2 (en) 2018-02-20

Similar Documents

Publication Publication Date Title
MX385464B (es) Composiciones microencapsuladas de cannabinoides
LTPA2021003I1 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su KIT
MY165124A (en) Semifluorinated alkane compositions
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
MX2014005510A (es) Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
UA115373C2 (uk) Стабільний рідкий склад amg 416 (велкалсетиду)
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
TR201902741T4 (tr) Kişisel Temizlik Bileşimleri
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
EP2953470A4 (en) 2,6,7-SUBSTITUTED PURINS AS HDM2 INHIBITORS
MX2015016603A (es) Composiciones de corticosteroides.
EA201591725A1 (ru) Твердые липидные наночастицы (ii)
MX2018007993A (es) Producto para el cuidado bucal y metodos para uso y fabricacion de este.
EA201500927A1 (ru) Твердые липидные наночастицы (i)
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
MX383014B (es) Formulaciones de antibióticos tópicas..
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
EA201890597A1 (ru) Содержащая цинеол водная композиция для назального применения